Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fisher, R.
Right arrow Articles by Regesta, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fisher, R.
Right arrow Articles by Regesta, G.
NEUROLOGY 1996;47:2S-5S
© 1996 American Academy of Neurology

Newer antiepileptic drugs as monotherapy

Data on vigabatrin

Robert Fisher, MD, PhD, Reeta Kalviainen, MD, PhD, Paolo Tanganelli, MD and Giovanni Regesta, MD

From the Barrow Neurological Institute (Dr. Fisher), St. Joseph's Hospital, Phoenix, AZ; the A.I. Virtanen Institute and the Department of Neurology (Dr. Kalviainen), the University of Kuopio, Kuopio, Finland; and the Department of Neurology (Drs. Tanganelli and Regesta), Epilepsy Center, San Martino Hospital, Genova, Italy.
Address correspondence and reprint requests to Dr. Robert Fisher, Chief, Neurophysiology, Barrow Neurological Institute, 222 West Thomas Road, Suite 200, Phoenix, AZ 85103.

Abstract.

Studies examining the use of vigabatrin as monotherapy for the treatment of epilepsy are relatively scarce, and of the few that have been reported, only two were of sufficient size to provide definitive data.In both trials, vigabatrin was compared with carbamazepine for efficacy and safety. In one of these studies, carbamazepine was found to be more effective than vigabatrin in reducing seizure frequency, and the two were found to be comparably efficacious in the other study. What differed significantly, however, was vigabatrin's favorable safety profile. Vigabatrin appears to be a reasonable choice for single-drug therapy in the treatment of certain types of seizures. In other patients, it remains useful as an adjunct to other antiepileptic drugs.

NEUROLOGY 1996;47(Suppl 1): S2-S5






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by AAN Enterprises, Inc.